Tumor-suppressor genes in pancreatic cancer

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 5, Issue 4, 1998, Pages 383-391

  Hruban, Ralph H ^a   Offerhaus, G Johan A ^b   Kern, Scott E ^a   Goggins, Michael ^a   Wilentz, Robb E ^a   Yeo, Charles J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cancer; Genes; Neoplasia; Pancreas; Pancreatic

Indexed keywords

TUMOR PROTEIN;

ADENOCARCINOMA; CELL CYCLE; GENETICS; HUMAN; KARYOTYPING; MUTATION; ONCOGENE; PANCREAS TUMOR; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL CYCLE; GENES, TUMOR SUPPRESSOR; HUMANS; KARYOTYPING; MUTATION; NEOPLASM PROTEINS; ONCOGENES; PANCREATIC NEOPLASMS;

EID: 0032242497     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005340050062     Document Type: Article

References (75)

1. Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin North Am 7:1-23
2. Goggins M, Offerhaus GJA, Hilgers W, Griffin CA, Shekher M, Tang D, Sohn TA, Yeo CJ, Kern SE, Hruban RH (1998) Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type k-ras and characteristic histopathology: Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152:1501-1507
3. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734
4. Hruban RH, van Mansfeld ADM, Offerhaus GJA, van Weering DHJ, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
5. Fearon ER (1997) Tumor suppressor genes. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw Hill, New York, pp 229-236
6. Griffin CA, Hruban RH, Morsberger L, Ellingham T, Long PP, Jaffee EM, Hauda KM, Bohlander SK, Yeo CJ (1995) Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 55:2394-2399
7. Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH (1997) The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 150:383-391
8. Griffin CA, Hruban RH, Long PP, Morsberger LA, Douna-Issa F, Yeo CJ (1994) Chromosome abnormalities in pancreatic adenocarcinoma. Genes, Chromosom Cancer 9:93-100
9. Morsberger LA, Griffin CA, Jaffee EM, et al (1997) Analysis of pancreatic carcinoma cell lines by comparative genomic hybridization. Mod Pathol 10:855
10. Green ED, Cox DR, Myers RM (1997) The human genome project and its impact on the study of human disease. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw Hill, New York, pp 33-64
11. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1995) Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55:4670-4675
12. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711
13. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70:523-526
14. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
15. Bates S, Vousden KH (1996) p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6:12-18
16. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948
17. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C (1991) Wild-type p53 activates transcription in vitro. Nature 358:83-86
18. 1 arrest and apoptosis. Cancer Res 54:1169-1174
19. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
20. Slebos RJC, Ceba HM, Kern SE, Hruban RH (1998) Molecular genetics of pancreas cancer. In: Sarkar F, Dugan M (eds) Pancreatic cancer. Molecular and clinical management prospects. Eton, Natick, MA pp 65-82
21. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, Umlauft F, Grunewald K (1996) p53, ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 74:279-289
22. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez M, Buchler M, Beger HG, Korc M (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 69:151-160
23. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele H-G, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H, Deppert W (1993) p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298
24. Pellegata NS, Sessa F, Renault B, Bonato MS, Leone BE, Solcia E, Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556-1560
25. Rall CJN, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK (1996) Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 12:10-17
26. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033
27. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S (1993) Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534-1543
28. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M (1994) p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 14:2477-2483
29. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C (1996) Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 53:104-111
30. Boschman CR, Stryker S, Reddy JK, Rao MS (1994) Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 145:1291-1295
31. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, Cameron JL, Offerhaus GJA (1994) Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 101:684-688
32. Lee EU, Cibull ML, O'Daniel-Pierce E, Strodel WE, Jennings CD (1995) Expression of p53 protein in pancreatic adenocarcinoma. Int J Pancreatol 17:237-242
33. Lee CS, Rush M, Charalambous D, Rode J (1993) Alimentary tract and pancreas. Immunohistochemical demonstration of the p53 tumor suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 8:465-469
34. Clurman BE, Roberts JM (1997) Cell cycle control: An overview. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw Hill, New York, pp 175-192
35. Riley DJ, Lee E, Lee WH (1994) The retinoblastoma protein: More than a tumor suppressor. Annu Rev Cell Biol 10:1-29
36. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day IRS, Johnson BE, Skolnick M (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
37. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130
38. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32
39. Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA, Goodfellow PJ (1996) Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst 88:680-682
40. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ (1995) Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes, Chromosom Cancer 14:189-195
41. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, Sawabu N (1997) Frequent loss of pl6 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 3:1473-1477
42. Huang L, Goodrow TL, Zhang S, Klein-Szanto AJP, Chang H, Ruggeri BA (1996) Deletion and mutation analyses of the P16/ MTS-1 tumor-suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 56:1137-1141
43. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W (1996) Frequent codeletion of p16/MTS1 and p15/ MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110:1215-1224
44. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumor-suppressor p16/ CDKN2/MTS1 in human cancers. Nature Medicine 1:686-692
45. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, daCosta LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353
46. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai JL, Kern SE, Kinzler KW, Vogelstein B (1998) Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 95:2412-2416
47. Yu HC, Shetty J (1985) Mucinous cystic neoplasm of the pancreas with high carcinoembryonic antigen. Arch Pathol Lab Med 109:375-377
48. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J (1996) Partnership between DPC4 and SMAD proteins in TGFβ signalling pathways. Nature 383:832-836
49. Zhang Y, Feng XH, Wu RY, Derynck R (1996) Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383:168-172
50. Moskaluk CA, Kern SE (1996) Cancer gets Mad: DPC4 and other TGF beta; pathway genes in human cancer. Biochim Biophys Acta 1288:M31-M33
51. Polyak K (1996) Negative regulation of cell growth by TGF β. Biochim Biophys Acta 1242:185-199
52. White RL (1998) Tumor suppressing pathways. Cell 92:591-592
53. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Ape genes. Cell 92:645-656
54. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA, Meltzer PS, Hahn SA, Kern SE (1996) DPC4 gene in various tumor types. Cancer Res 56:2527-2530
55. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz S, Kinzler KW, Vogelstein B (1996) Mad-related genes in the human. Nature Genetics 13:347-349
56. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics 13:343-346
57. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T (1996) Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56:2718-2720
58. Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, Saji S (1996) Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 111:1369-1372
59. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364
60. Ozcelik H, Schmocker B, DiNicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genetics 16:17-18
61. Schutte M, daCosta LT, Hahn SA, Moskaluk C, Hoque ATMS, Rozenblum E, Weinstein CL, Meltzer PS, Trent JM, Yeo CJ, Hruban RH, Kern SE (1995) Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 92:5950-5954
62. Schutte M, Rozenblum E, Moskaluk CA, Guan X, Hoque ATMS, Hahn SA, daCosta LT, deJong PJ, Kern SE (1995) An integrated high-resolution physical map of the DPC/ BRCA2 region at chromosome 13q12. Cancer Res 55:4570-4574
63. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genetics 18:38-43
64. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH, Luk GD (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316:1511-1514
65. Höglund M, Gorunova L, Andrén-Sandberg A, Dawiskiba S, Mitelman F, Johansson B (1998) Cytogenetic and fluorescence in situ hybridization analyses of chromosomes 19 aberrations in pancreatic carcinomas: Frequent loss of 19p13.3 and gain of 19q13.1-13.2. Genes Chromosom Cancer 21:8-16
66. Su GH, Hilgers W, Shekher M, Tang D, Yeo CJ, Hruban RH, Kern SE (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. Cancer Res 58:2339-2342
67. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH (1998) Progression of pancreatic intraductal neoplasias (high-grade PanIN) to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 22:163-169
68. Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143
69. Goggins M, Hruban RH, Kern SE (1997) Relationship of BRCA2 germline mutation and pancreatic cancer intra-ductal lesions. Fourth Annual SPORE Meeting 4:30
70. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark J WH, Tucker MA (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16(INK4) mutations. N Engl J Med 333:970-974
71. Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975-977
72. INK4a and CDK4 mutations in familial pancreatic carcinoma. Hum Mutation (In press)
73. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56:3409-3414
74. Phelan CM, Lancaster J, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher M, Dole K, Lounis H, Warner E, Goss P (1996) Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genetics 13:120-122
75. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavitigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genetics 13:117-119